Atractyliretin
| Internal ID | c15f28ee-08fe-43da-8bd6-11051b89c412 |
| Taxonomy | Lipids and lipid-like molecules > Prenol lipids > Diterpenoids > Kaurane diterpenoids |
| IUPAC Name | (4R,5R,7R,9R,10R,13S,14R)-14-formyl-7-hydroxy-9-methyltetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylic acid |
| SMILES (Canonical) | CC12CC(CC(C1CCC34C2CCC(C3)C(C4)C=O)C(=O)O)O |
| SMILES (Isomeric) | C[C@@]12C[C@@H](C[C@H]([C@H]1CCC34[C@H]2CC[C@@H](C3)[C@@H](C4)C=O)C(=O)O)O |
| InChI | InChI=1S/C19H28O4/c1-18-9-13(21)6-14(17(22)23)15(18)4-5-19-7-11(2-3-16(18)19)12(8-19)10-20/h10-16,21H,2-9H2,1H3,(H,22,23)/t11-,12-,13+,14+,15+,16-,18+,19?/m0/s1 |
| InChI Key | ZIYOPAJORMZIKJ-SGYYOSLQSA-N |
| Popularity | 0 references in papers |
| Molecular Formula | C19H28O4 |
| Molecular Weight | 320.40 g/mol |
| Exact Mass | 320.19875937 g/mol |
| Topological Polar Surface Area (TPSA) | 74.60 Ų |
| XlogP | 3.00 |
| Atomic LogP (AlogP) | 2.88 |
| H-Bond Acceptor | 3 |
| H-Bond Donor | 2 |
| Rotatable Bonds | 2 |
| 110990-68-6 |
| (-)-Atractylliretin |
| 19-Norkauran-18-oicacid, 2-hydroxy-17-oxo-, (2beta,4alpha,16alpha)- |
| Target | Value | Probability (raw) | Probability (%) |
|---|---|---|---|
| Human Intestinal Absorption | + | 0.9833 | 98.33% |
| Caco-2 | - | 0.5685 | 56.85% |
| Blood Brain Barrier | - | 0.5500 | 55.00% |
| Human oral bioavailability | - | 0.5143 | 51.43% |
| Subcellular localzation | Mitochondria | 0.7795 | 77.95% |
| OATP2B1 inhibitior | - | 0.8569 | 85.69% |
| OATP1B1 inhibitior | + | 0.8888 | 88.88% |
| OATP1B3 inhibitior | + | 0.9425 | 94.25% |
| MATE1 inhibitior | - | 0.9800 | 98.00% |
| OCT2 inhibitior | - | 0.7375 | 73.75% |
| BSEP inhibitior | - | 0.7333 | 73.33% |
| P-glycoprotein inhibitior | - | 0.8461 | 84.61% |
| P-glycoprotein substrate | - | 0.7365 | 73.65% |
| CYP3A4 substrate | + | 0.6714 | 67.14% |
| CYP2C9 substrate | - | 0.8133 | 81.33% |
| CYP2D6 substrate | - | 0.8381 | 83.81% |
| CYP3A4 inhibition | - | 0.9304 | 93.04% |
| CYP2C9 inhibition | - | 0.9425 | 94.25% |
| CYP2C19 inhibition | - | 0.9504 | 95.04% |
| CYP2D6 inhibition | - | 0.9672 | 96.72% |
| CYP1A2 inhibition | - | 0.7818 | 78.18% |
| CYP2C8 inhibition | - | 0.5899 | 58.99% |
| CYP inhibitory promiscuity | - | 0.9919 | 99.19% |
| UGT catelyzed | + | 0.7000 | 70.00% |
| Carcinogenicity (binary) | - | 1.0000 | 100.00% |
| Carcinogenicity (trinary) | Non-required | 0.6282 | 62.82% |
| Eye corrosion | - | 0.9905 | 99.05% |
| Eye irritation | - | 0.9410 | 94.10% |
| Skin irritation | + | 0.5554 | 55.54% |
| Skin corrosion | - | 0.8849 | 88.49% |
| Ames mutagenesis | - | 0.7200 | 72.00% |
| Human Ether-a-go-go-Related Gene inhibition | - | 0.7439 | 74.39% |
| Micronuclear | - | 0.8400 | 84.00% |
| Hepatotoxicity | - | 0.5504 | 55.04% |
| skin sensitisation | - | 0.8648 | 86.48% |
| Respiratory toxicity | + | 0.6000 | 60.00% |
| Reproductive toxicity | + | 0.8556 | 85.56% |
| Mitochondrial toxicity | + | 0.8750 | 87.50% |
| Nephrotoxicity | - | 0.8044 | 80.44% |
| Acute Oral Toxicity (c) | III | 0.7062 | 70.62% |
| Estrogen receptor binding | + | 0.8500 | 85.00% |
| Androgen receptor binding | + | 0.6538 | 65.38% |
| Thyroid receptor binding | + | 0.5921 | 59.21% |
| Glucocorticoid receptor binding | + | 0.7615 | 76.15% |
| Aromatase binding | + | 0.5456 | 54.56% |
| PPAR gamma | + | 0.5927 | 59.27% |
| Honey bee toxicity | - | 0.7906 | 79.06% |
| Biodegradation | - | 0.6500 | 65.00% |
| Crustacea aquatic toxicity | - | 0.5300 | 53.00% |
| Fish aquatic toxicity | + | 0.9783 | 97.83% |
Proven Targets:
| CHEMBL ID | UniProt ID | Name | Min activity | Assay type | Source |
|---|---|---|---|---|---|
| No proven targets yet! | |||||
Predicted Targets (via Super-PRED):
| CHEMBL ID | UniProt ID | Name | Probability | Model accuracy |
|---|---|---|---|---|
| CHEMBL253 | P34972 | Cannabinoid CB2 receptor | 96.53% | 97.25% |
| CHEMBL221 | P23219 | Cyclooxygenase-1 | 95.29% | 90.17% |
| CHEMBL3251 | P19838 | Nuclear factor NF-kappa-B p105 subunit | 93.47% | 96.09% |
| CHEMBL284 | P27487 | Dipeptidyl peptidase IV | 91.24% | 95.69% |
| CHEMBL218 | P21554 | Cannabinoid CB1 receptor | 89.10% | 96.61% |
| CHEMBL340 | P08684 | Cytochrome P450 3A4 | 88.22% | 91.19% |
| CHEMBL226 | P30542 | Adenosine A1 receptor | 87.71% | 95.93% |
| CHEMBL3807 | P17706 | T-cell protein-tyrosine phosphatase | 86.27% | 93.00% |
| CHEMBL4303 | P08238 | Heat shock protein HSP 90-beta | 85.57% | 96.77% |
| CHEMBL1994 | P08235 | Mineralocorticoid receptor | 84.77% | 100.00% |
| CHEMBL5619 | P27695 | DNA-(apurinic or apyrimidinic site) lyase | 83.72% | 91.11% |
| CHEMBL3137262 | O60341 | LSD1/CoREST complex | 83.43% | 97.09% |
| CHEMBL6136 | O60341 | Lysine-specific histone demethylase 1 | 82.75% | 95.58% |
| CHEMBL2179 | P04062 | Beta-glucocerebrosidase | 81.74% | 85.31% |
| CHEMBL268 | P43235 | Cathepsin K | 81.61% | 96.85% |
| CHEMBL4685 | P14902 | Indoleamine 2,3-dioxygenase | 81.35% | 96.38% |
| CHEMBL3091268 | Q92753 | Nuclear receptor ROR-beta | 80.44% | 95.50% |
| PubChem | 183150 |
| LOTUS | LTS0032495 |
| wikiData | Q105377680 |